| ADI-SPS-771PE-050 | 50 µg | 270.00 USD |  |
||
| ADI-SPS-771PE-200 | 200 µg | 587.00 USD | |
||
| Do you need bulk/larger quantities? | |||||
| Alternative Name: | HSP86, Heat shock protein 90α |
| Host: | Rabbit |
| Immunogen: | Synthetic peptide corresponding to a portion of mouse Hsp86. |
| UniProt ID: | P07901 |
| GenBank ID: | X16857 |
| Source: | Purified from rabbit serum. |
| Species reactivity: | Human, Mouse, Rat Beluga, Bovine, Dog, Fish, Guinea pig, Hamster, Monkey, Porcine, Rabbit, Sheep, Xenopus |
| Applications: | Flow Cytometry |
| Recommended Dilutions/Conditions: | Flow Cytometry (1:100) Suggested dilutions/conditions may not be available for all applications. Optimal conditions must be determined individually for each application. |
| Purity Detail: | Protein A affinity purified. |
| Formulation: | Liquid. In PBS, pH 7.2, containing 0.09% sodium azide. |
| Handling: | Avoid vigorous centrifugation and vortexing. Do not freeze. Protect from light. |
| Shipping: | Blue Ice Not Frozen |
| Long Term Storage: | +4°C |
| Scientific Background: | The Hsp90 family of heat shock proteins represents one of the most abundantly expressed and highly conserved families of cellular chaperones whose expression can be upregulated under conditions of cellular stress, and includes cytoplasmic (Hsp90-α/β), ER (grp94), and mitochondrial (TRAP1) localized members. Structurally, Hsp90 is characterized by an N-terminal ATP-binding domain, a medial substrate-binding domain, and a C-terminal dimerization motif. Hsp90 dimers function in cooperation with cochaperones (e.g. Hsp40, Hsp70, Hop, p23) to stabilize a multitude of client protein substrates, including steroid hormone receptors, protein kinases, and transcription factors. The essential binding and hydrolysis of ATP by Hsp90 is inhibited by ansamycin drugs (e.g. geldanamycin, 17-AAG) which occupy the N-terminal Hsp90 nucleotide-binding pocket. Many Hsp90 client proteins such as erbB2/Her-2, c-raf, bcr-abl, p53, and hTERT, are members of well characterized oncogenic pathways, making Hsp90 inhibitors useful anticancer agents. |
| Regulatory Status: | RUO - Research Use Only |
